NMDA receptor antagonist acting at the glycine site. Potent competitive inhibitor of L-glutamate transport into synaptic vesicles. Also available as part of the NMDA Receptor - Glycine Site Tocriset™. 7-Chlorokynurenic acid sodium salt (Cat. No. 3697) also available.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 223.62. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||4.47 mL||22.36 mL||44.72 mL|
|5 mM||0.89 mL||4.47 mL||8.94 mL|
|10 mM||0.45 mL||2.24 mL||4.47 mL|
|50 mM||0.09 mL||0.45 mL||0.89 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Bartlett et al (1998) Substituted quinolines as inhibitors of L-glutamate transport into synaptic vesicles. Neuropharmacology 37 839 PMID: 9776380
Kemp et al (1988) 7-Chlorokynurenic acid is a selective antagonist of the glycine modulatory site of the NMDA receptor complex. Proc.Natl.Acad.Sci.U.S.A. 85 6547 PMID: 2842779
Kretschmer et al (1995) Behavioral and neurochemical actions of the strychnine-insensitive glycine receptor antagonist, 7-chlorokynurenate, in rats. Eur.J.Pharmacol. 280 37 PMID: 7498252
If you know of a relevant reference for 7-Chlorokynurenic acid, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: 7-Chlorokynurenic acid, supplier, Potent, competitive, inhibitors, inhibits, L-glutamate, uptake, NMDA, antagonists, glycine, site, EAAT, Excitatory, Amino, Acid, Transporters, GLAST, GLT-1, Glutamate, Monoamine, Neurotransmitter, Receptors, N-Methyl-D-Aspartate, iGluR, Ionotropic, Glutamate, Transporters, Tocris Bioscience
6 Citations for 7-Chlorokynurenic acid
Citations are publications that use Tocris products. Selected citations for 7-Chlorokynurenic acid include:
Biase et al (2011) NMDA receptor signaling in oligodendrocyte progenitors is not required for oligodendrogenesis and myelination. Proc Natl Acad Sci U S A 31 12650 PMID: 21880926
Baltan et al (2008) White matter vulnerability to ischemic injury increases with age because of enhanced excitotoxicity. J Neurosci 28 1479 PMID: 18256269
Vigot et al (2006) Differential compartmentalization and distinct functions of GABAB receptor variants. Neuron 50 589 PMID: 16701209
Shin et al (2006) Vasoconstrictive neurovascular coupling during focal ischemic depolarizations. J Cereb Blood Flow Metab 26 1018 PMID: 16340958
Casado et al (2000) Presynaptic N-methyl-D-aspartate receptors at the parallel fiber-Purkinje cell synapse. Proc Natl Acad Sci U S A 97 11593 PMID: 11016958
Tacconi et al (1993) Inhibition of [3H]-(+)-MK 801 binding to rat brain sections by CPP and 7-chlorokynurenic acid: an autoradiographic analysis. Br J Pharmacol 108 577 PMID: 8096780
Do you know of a great paper that uses 7-Chlorokynurenic acid from Tocris? If so please let us know.
Literature in this Area
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.